FDA’s Class II Classification of Muscular Dystrophy Newborn Screening Test
Gain in-depth insights into the FDA’s decision to classify the muscular dystrophy newborn screening test into class II, focusing on the implications for safety, effectiveness, and regulatory compliance. Learn about the special controls required and how this classification can streamline the regulatory process, ensuring innovative devices reach patients faster.
In this course you will learn the following:
* Understand the classification process and criteria for the muscular dystrophy newborn screening test.
* Identify the special controls and general controls applicable to the device.
* Recognize the impact of this classification on regulatory burdens and patient access to innovative devices.
NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.